Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 171 to 180 of 545 total matches.
Three Drugs for Atopic Dermatitis (Adbry, Cibinqo, and Rinvoq)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
.1 Dupilumab is
also approved for several other indications, including
add-on treatment in patients ...
The subcutaneously injected interleukin-13 (IL-13)
antagonist tralokinumab-ldrm (Adbry – Leo) and
the oral Janus kinase (JAK) inhibitors abrocitinib
(Cibinqo – Pfizer) and upadacitinib (Rinvoq – Abbvie)
have been approved by the FDA for treatment of
moderate to severe atopic dermatitis.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):51-5 doi:10.58347/tml.2023.1673b | Show Introduction Hide Introduction
Drugs for Sexually Transmitted Infections
The Medical Letter on Drugs and Therapeutics • Jun 27, 2022 (Issue 1653)
of the
indications and dosages recommended here have
not been approved by the FDA (see Table 1).
PARTNER TREATMENT ...
This article includes recommendations for management
of most sexually transmitted infections (STIs)
other than HIV and viral hepatitis. Some of the
indications and dosages recommended here have
not been approved by the FDA (see Table 1).
Brolucizumab (Beovu) for Age-Related Macular Degeneration
The Medical Letter on Drugs and Therapeutics • Feb 10, 2020 (Issue 1591)
effective and has not
been shown to improve vision.1,2
CLINICAL STUDIES — FDA approval of brolucizumab ...
Brolucizumab-dbll (Beovu — Novartis), a vascular
endothelial growth factor (VEGF) inhibitor, has been
approved by the FDA as an intravitreal injection for
treatment of neovascular (wet) age-related macular
degeneration (AMD). It is the fourth VEGF inhibitor to
be approved in the US for this indication; bevacizumab
(Avastin, and others), a VEGF inhibitor FDA-approved
for treatment of breast cancer and other malignancies,
has been used off-label for this indication for years.
IV Amisulpride (Barhemsys) for Postoperative Nausea and Vomiting
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020 (Issue 1614)
or motion sickness,
female sex, nonsmoking status, age ...
The FDA has approved IV amisulpride (Barhemsys –
Acacia), a selective dopamine-2 and -3 (D2/D3) receptor
antagonist, for prevention and treatment of postoperative
nausea and vomiting (PONV) in adults. It is the first
antiemetic to be approved for rescue treatment of
PONV in patients who have symptoms despite receiving
antiemetic prophylaxis. Oral formulations of amisulpride
are available in Europe for treatment of schizophrenia
and acute psychotic episodes.
Lyumjev - A New Insulin Lispro for Diabetes
The Medical Letter on Drugs and Therapeutics • Oct 19, 2020 (Issue 1609)
–
Lilly), a faster-acting formulation of insulin lispro
(Humalog), for treatment of type 1 and type 2 ...
The FDA has approved insulin lispro-aabc (Lyumjev –
Lilly), a faster-acting formulation of insulin lispro
(Humalog), for treatment of type 1 and type 2 diabetes
in adults. Fiasp, a faster-acting formulation of insulin
aspart (Novolog), was approved in 2017.
Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
)
generic
375 mg ER caps Maintenance: 1.5 g PO once/day
Nausea, vomiting, diarrhea, headache ...
View the Table: Some Drugs for Inflammatory Bowel Disease
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e115-9 doi:10.58347/tml.2023.1680d | Show Introduction Hide Introduction
Bupivacaine/Meloxicam (Zynrelef) for Postsurgical Pain
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022 (Issue 1642)
, and short-acting
local anesthetics.1,2
Table 1. Zynrelef Clinical Trial Results
Regimen1 Pain Intensity ...
The FDA has approved a fixed-dose combination
of the amide local anesthetic bupivacaine and
the nonsteroidal anti-inflammatory drug (NSAID)
meloxicam as an extended-release (ER) solution
(Zynrelef – Heron) for single-dose, intraoperative,
soft-tissue or periarticular instillation to provide
postsurgical analgesia for up to 72 hours in adults
undergoing foot and ankle, small-to-medium open
abdominal, or lower extremity total joint arthroplasty
surgical procedures.
Oteseconazole (Vivjoa) for Recurrent Vulvovaginal Candidiasis
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022 (Issue 1656)
in preventing further
recurrences for up to 1 year.
Adverse Effects: Most common were headache and nausea ...
The FDA has approved oteseconazole (Vivjoa –
Mycovia), a new oral azole antifungal, to reduce the incidence
of recurrent vulvovaginal candidiasis (RVVC)
in females with a history of RVVC. Oteseconazole is
the first drug to be approved in the US specifically for
treatment of RVVC.
In Brief: New Recommendations for Gonococcal Infection
The Medical Letter on Drugs and Therapeutics • May 03, 2021 (Issue 1623)
for patients with uncomplicated
urogenital, rectal, or pharyngeal gonorrhea.1
RATIONALE — Previous CDC ...
The CDC has issued new recommendations for
treatment of gonococcal infection. A single 500-mg
IM dose (1000 mg in patients weighing ≥150 kg) of the
third-generation cephalosporin ceftriaxone is now the
treatment of choice for patients with uncomplicated
urogenital, rectal, or pharyngeal gonorrhea.
In Brief: Pfizer/BioNTech COVID-19 Vaccine Authorized for Adolescents 12-15 Years Old
The Medical Letter on Drugs and Therapeutics • May 31, 2021 (Issue 1625)
-19 vaccine to include adolescents 12-15
years old.1 The vaccine has been authorized for use ...
On May 10, 2021, the FDA expanded its Emergency
Use Authorization (EUA) for the Pfizer/BioNTech
mRNA-based COVID-19 vaccine to include adolescents
12-15 years old.1The vaccine has been
authorized for use in persons ≥16 years old since
December 2020.